S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:AFMD

Affimed - AFMD Stock Forecast, Price & News

$0.74
-0.02 (-2.63%)
(As of 03/20/2023 08:20 AM ET)
Add
Compare
Today's Range
$0.74
$0.74
50-Day Range
$0.76
$1.29
52-Week Range
$0.74
$5.10
Volume
1,088 shs
Average Volume
1.27 million shs
Market Capitalization
$91.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Affimed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
667.5% Upside
$5.83 Price Target
Short Interest
Healthy
3.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
-0.02mentions of Affimed in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

296th out of 983 stocks

Pharmaceutical Preparations Industry

128th out of 480 stocks


AFMD stock logo

About Affimed (NASDAQ:AFMD) Stock

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Stock News Headlines

Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Brokerages Set Affimed (NASDAQ:AFMD) Target Price at $5.83
SVB Securities Keeps Their Buy Rating on Affimed (AFMD)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Why Shares of Affimed Fell Thursday
Affimed Third Quarter 2022 Earnings: Beats Expectations
Why Affimed Stock Plummeted by Over 16% Today
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings
11/10/2021
Today
3/20/2023
Next Earnings (Confirmed)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
197
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.83
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+667.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-68,060,000.00
Net Margins
-189.04%
Pretax Margin
-190.34%

Debt

Sales & Book Value

Annual Sales
$47.76 million
Book Value
$1.30 per share

Miscellaneous

Free Float
118,730,000
Market Cap
$93.80 million
Optionable
Optionable
Beta
2.58

Key Executives

  • Adolf Hoess
    Chief Executive Officer
  • Wolfgang Fischer
    Chief Operating Officer
  • Angus W. Smith
    Chief Financial Officer
  • Andreas Harstrick
    Chief Medical Officer
  • Arndt Schottelius
    Chief Scientific Officer













AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price forecast for 2023?

6 equities research analysts have issued 12-month price objectives for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $8.00. On average, they predict the company's share price to reach $5.83 in the next year. This suggests a possible upside of 667.5% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2023?

Affimed's stock was trading at $1.24 at the beginning of 2023. Since then, AFMD stock has decreased by 38.7% and is now trading at $0.76.
View the best growth stocks for 2023 here
.

Are investors shorting Affimed?

Affimed saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,780,000 shares, an increase of 21.5% from the February 13th total of 3,110,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the days-to-cover ratio is currently 2.2 days.
View Affimed's Short Interest
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our AFMD earnings forecast
.

How can I listen to Affimed's earnings call?

Affimed will be holding an earnings conference call on Thursday, March 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to analyst estimates of $11.79 million. Affimed had a negative net margin of 189.04% and a negative trailing twelve-month return on equity of 48.46%. During the same quarter in the prior year, the business posted ($0.08) EPS.

What ETFs hold Affimed's stock?

ETFs with the largest weight of Affimed (NASDAQ:AFMD) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ALPS Medical Breakthroughs ETF (SBIO).

What other stocks do shareholders of Affimed own?
What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (7.29%), Point72 Asset Management L.P. (3.41%), Boone Capital Management LLC (2.33%), Morgan Stanley (1.71%), Millennium Management LLC (1.67%) and Geode Capital Management LLC (1.11%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $0.76.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $93.80 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How many employees does Affimed have?

The company employs 197 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 3/20/2023 by MarketBeat.com Staff